{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:58:40Z","timestamp":1791845920686,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.beha.2017.01.002","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T20:18:47Z","timestamp":1485807527000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Clinical aspects and therapy of gastrointestinal MALT lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Catherine","family":"Thieblemont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beha.2017.01.002_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri3383","article-title":"Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes","volume":"13","author":"Cerutti","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2017.01.002_bib2","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2008"},{"issue":"11","key":"10.1016\/j.beha.2017.01.002_bib3","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2017.01.002_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.beha.2017.01.002_bib5","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1158\/1078-0432.CCR-14-0496","article-title":"Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas","volume":"20","author":"Zucca","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2017.01.002_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa031887","article-title":"Immunoproliferative small intestinal disease associated with Campylobacter jejuni","volume":"350","author":"Lecuit","year":"2004","journal-title":"N Engl J Med"},{"issue":"8776","key":"10.1016\/j.beha.2017.01.002_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0140-6736(91)92035-Z","article-title":"Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma","volume":"338","author":"Wotherspoon","year":"1991","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2017.01.002_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/annonc\/mdp402","article-title":"Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2017.01.002_bib9","doi-asserted-by":"crossref","first-page":"638185","DOI":"10.1155\/2012\/638185","article-title":"Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy","volume":"2012","author":"Arcaini","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"12","key":"10.1016\/j.beha.2017.01.002_bib10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJM199803193381205","article-title":"Molecular analysis of the progression from Helicobacter pylori- associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach","volume":"338","author":"Zucca","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2017.01.002_bib11","first-page":"109","article-title":"Helicobacter pylori and mucosa-associated lymphoid tissue: what's new","volume":"2013","author":"Kuo","year":"2013","journal-title":"ASH Educ Program Book"},{"issue":"3","key":"10.1016\/j.beha.2017.01.002_bib12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.chom.2014.02.008","article-title":"Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis","volume":"15","author":"Hatakeyama","year":"2014","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.beha.2017.01.002_bib13","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0016-5085(97)70028-3","article-title":"MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein","volume":"112","author":"Eck","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.beha.2017.01.002_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2002-12-3803","article-title":"Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity","volume":"102","author":"Rollinson","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2017.01.002_bib15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.2010.08518.x","article-title":"A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk","volume":"152","author":"Hosgood","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2017.01.002_bib16","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2002-11-3502","article-title":"Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma","volume":"102","author":"Ye","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.01.002_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semcancer.2013.11.005","article-title":"Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type","volume":"24","author":"Thieblemont","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"18","key":"10.1016\/j.beha.2017.01.002_bib18","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2012-06-438424","article-title":"Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial","volume":"120","author":"Ferreri","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2017.01.002_bib19","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1200\/JCO.2001.19.7.2041","article-title":"Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection","volume":"19","author":"Morgner","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2017.01.002_bib20","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication","volume":"122","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.beha.2017.01.002_bib21","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2004.10.087","article-title":"Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas","volume":"22","author":"Kuo","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.01.002_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.2005.081117","article-title":"Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H. pylori eradication","volume":"55","author":"Ye","year":"2006","journal-title":"Gut"},{"issue":"16","key":"10.1016\/j.beha.2017.01.002_bib23","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2006.05.6150","article-title":"Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma","volume":"24","author":"Sagaert","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2017.01.002_bib24","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.leu.2404244","article-title":"Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation","volume":"20","author":"Haralambieva","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2017.01.002_bib25","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"214","article-title":"Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","author":"Isaacson","year":"2008"},{"issue":"6","key":"10.1016\/j.beha.2017.01.002_bib26","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2004-07-2755","article-title":"Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms","volume":"105","author":"Al-Saleem","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2017.01.002_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.semcancer.2013.09.004","article-title":"Marginal zone lymphomas and infectious agents","volume":"23","author":"Ferreri","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.beha.2017.01.002_bib28","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Rinaldi","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2017.01.002_bib29","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa- associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2017.01.002_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0092-8674(00)80957-5","article-title":"Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types","volume":"96","author":"Willis","year":"1999","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.beha.2017.01.002_bib31","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2002-09-2963","article-title":"T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma","volume":"101","author":"Streubel","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2017.01.002_bib32","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.leu.2403644","article-title":"T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma","volume":"19","author":"Streubel","year":"2005","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2017.01.002_bib33","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/01.pas.0000213275.60962.2a","article-title":"The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America","volume":"30","author":"Remstein","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.beha.2017.01.002_bib34","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/sj.leu.2403122","article-title":"Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT\/MALT1 in MALT lymphomas","volume":"17","author":"Murga Penas","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2017.01.002_bib35","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-{kappa}B signaling in lymphoma: mechanisms, consequences and therapeutic implications","volume":"109","author":"Jost","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2017.01.002_bib36","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1158\/0008-5472.CAN-05-4590","article-title":"Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination","volume":"66","author":"Baens","year":"2006","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.beha.2017.01.002_bib37","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF-\u039aB negative regulator TNFAIP3 (A20) is commonly inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas","volume":"113","author":"Novak","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2017.01.002_bib38","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2008-12-194852","article-title":"TNFAIP3\/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas","volume":"114","author":"Honma","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2017.01.002_bib39","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3324\/haematol.2011.040402","article-title":"Genomic profiles of MALT lymphomas: variability across anatomic sites","volume":"96","author":"Kwee","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2017.01.002_bib40","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1349-7006.2009.01128.x","article-title":"Translocation t(11;18)(q21;q21) in gastric B-cell lymphomas","volume":"100","author":"Toracchio","year":"2009","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.beha.2017.01.002_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nri1629","article-title":"Control of lymphocyte development by nuclear factor-kappaB","volume":"5","author":"Siebenlist","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.beha.2017.01.002_bib42","first-page":"1190","article-title":"Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion","volume":"10","author":"Du","year":"1996","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2017.01.002_bib43","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.1997.15.4.1624","article-title":"Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients","volume":"15","author":"Thieblemont","year":"1997","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.beha.2017.01.002_bib44","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","article-title":"Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience","volume":"24","author":"Raderer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2017.01.002_bib45","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"issue":"S1","key":"10.1016\/j.beha.2017.01.002_bib46","first-page":"130","article-title":"Clinical outcomes and patterns of relapse in 320 patients with early and advanced-stage marginal zone lymphoma: the role of radiotherapy","volume":"31","author":"Teckie","year":"2013","journal-title":"Hematol Oncol"},{"issue":"9249","key":"10.1016\/j.beha.2017.01.002_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)03571-6","article-title":"Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy","volume":"357","author":"Liu","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2017.01.002_bib48","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","article-title":"Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed","volume":"95","author":"Thieblemont","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2017.01.002_bib49","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.beha.2017.01.002_bib50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.5098.5098","article-title":"Outcome of transformed marginal zone lymphomas treated in the rituximab era","volume":"126","author":"Rusconi","year":"2015","journal-title":"Blood"},{"issue":"Suppl. 6","key":"10.1016\/j.beha.2017.01.002_bib51","doi-asserted-by":"crossref","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.01.002_bib52","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.01.002_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2152","article-title":"Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis","volume":"33","author":"Treglia","year":"2015","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.01.002_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hon.2181","article-title":"Role of 18F-FDG-PET\/CT in the management of marginal zone B cell lymphoma","volume":"33","author":"Carrillo-Cruz","year":"2015","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.01.002_bib55","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/asheducation-2014.1.590","article-title":"Hepatitis C virus-associated B-cell non-Hodgkin lymphomas","volume":"2014","author":"Vannata","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.beha.2017.01.002_bib56","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type","volume":"20","author":"Stathis","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2017.01.002_bib57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2009.07.017","article-title":"Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma","volume":"8","author":"Zullo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.beha.2017.01.002_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","article-title":"Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan","volume":"61","author":"Nakamura","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.beha.2017.01.002_bib59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2008.07486.x","article-title":"Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial","volume":"144","author":"Hancock","year":"2009","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.beha.2017.01.002_bib60","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.ejca.2008.07.005","article-title":"Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study","volume":"44","author":"Capelle","year":"2008","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2017.01.002_bib61","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1053\/j.gastro.2012.06.035","article-title":"Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years","volume":"143","author":"W\u00fcndisch","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.beha.2017.01.002_bib62","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MCG.0b013e318286ff72","article-title":"Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review","volume":"47","author":"Zullo","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.beha.2017.01.002_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.743","article-title":"Radiation therapy for localized low-grade non-Hodgkin's lymphomas","volume":"23","author":"Tsang","year":"2005","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.beha.2017.01.002_bib64","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2017.01.002_bib65","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2017.01.002_bib66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"issue":"S1","key":"10.1016\/j.beha.2017.01.002_bib67","first-page":"129","article-title":"Bendamustine plus rituximab in first line systemic treatment for extranodal MALT lymphoma: final results of phase II trial of the Spanish lymphoma study group (GELTAMO)","volume":"31","author":"Salar","year":"2013","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.beha.2017.01.002_bib68","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","author":"Brown","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2017.01.002_bib69","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/asheducation-2005.1.307","article-title":"Clinical presentation and management of marginal zone lymphomas","author":"Thieblemont","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2017.01.002_bib70","first-page":"33","article-title":"Immunoproliferative small intestinal disease (IPSID): relationshipsith alpha-chain disease and \u201cMediterranean\u201dlymphomas","volume":"2","author":"Rambaud","year":"1989","journal-title":"Gastoenterol Int"},{"key":"10.1016\/j.beha.2017.01.002_bib71","first-page":"1251","article-title":"Treatment of alpha chain disease: results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group","volume":"63","author":"Ben-Ayed","year":"1989","journal-title":"Can-cer"},{"key":"10.1016\/j.beha.2017.01.002_bib72","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<8::AID-CNCR2>3.0.CO;2-T","article-title":"Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience","volume":"80","author":"Akbulut","year":"1997","journal-title":"Cancer"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261730004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261730004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T05:33:04Z","timestamp":1601530384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169261730004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":72,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S152169261730004X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.01.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical aspects and therapy of gastrointestinal MALT lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}